Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Eris Lifesciences Limited

Eris is a pharmaceutical company that focuses on patient care, pioneering studies, and health & living solutions.

Eris

Eris Lifesciences Ltd is a publicly listed Indian pharmaceutical company and is a leading player in the domestic branded formulations market. Ranked #21 in the IPM, Eris has established a leading presence in its core cardio-metabolic franchise in just 16 years from inception. Eris is also successfully diversifying its business with 3 emerging therapies (Dermatology, Neuropsychiatry and Gynaecology) accounting for 26% of its revenue.

We began our journey 16 years ago in 2007 with the vision to make a meaningful impact in the management of chronic lifestyle related diseases. Today Chronic and Sub-chronic therapies account for ~ 87% of our revenue, and our product range spans ~ 90% of India’s Rs. 55,000+ crore chronic care market. Our business model is pivoted around specialist/ super specialist doctors and high end consulting physicians. We consistently endeavour to channel the advantages of cutting-edge medical knowledge to aid our clinicians and patients with better disease management options and outcomes

Chrys Capital

ERIS Lifesciences

Eris delivers 54% Q1 Revenue growth and 47% Q1 EBIDTA growth. Biocon business grows 14% in Q1 with significant margin expansion. Eris is now a Top-20 company in the IPM – gained 9 ranks since the IPO in 2017.

Eris delivers 37% Revenue growth and 30% PAT growth in Q4 FY24; Organic growth 15% in Branded Formulations.
#Q4Results #AnnualResults #Pharma #Powerofempathy #growth

Eris acquires Biocon Biologics’ India Branded Formulation business for INR 1242 cr. #eris #acquisition #powerofempathy #pharma

Eris Lifesciences expands its footprint in Sterile Injectables with the acquisition of 51% stake in Swiss Parenterals Ltd.
#eris #acquisition #powerofempathy #pharma

Eris delivers 15% Consolidated Revenue Growth with EBITDA margin of 36% in Q3 FY24; Branded formulations business clocks 37% EBITDA margin.
#q3fy24 #results #powerofempathy #growth

Eris announces H1 Revenue Growth of 13% and EBIDTA growth of 25%; Cash EPS grows 9.5%
#q2fy24 #results #eris #powerofempathy #growth

Eris acquires Biocon Divisions; Enters #Nephrology; Consolidates #Derma
#eris #powerofempathy #acquisition #pharma

IN:CO:ERIS